Home » Stocks » resTORbio

resTORbio, Inc. (TORC)

Stock Price: $2.40 USD 0.05 (1.91%)
Updated Jul 16, 2020 11:17 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 87.29M
Revenue (ttm) n/a
Net Income (ttm) -78.71M
Shares Out 36.45M
EPS (ttm) -2.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $2.40
Previous Close $2.35
Change ($) 0.05
Change (%) 1.91%
Day's Open 2.35
Day's Range 2.31 - 2.47
Day's Volume 332,602
52-Week Range 0.86 - 11.96

More Stats

Market Cap 87.29M
Enterprise Value 10.70M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 36.45M
Float 25.82M
EPS (basic) -2.28
EPS (diluted) -2.18
FCF / Share -2.11
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 560,879
Short Ratio 0.57
Short % of Float 2.01%
Beta 2.59
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.09
Revenue n/a
Operating Income -81.15M
Net Income -78.71M
Free Cash Flow -76.92M
Net Cash 76.59M
Net Cash / Share 2.10
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -45.04%
ROE -72.85%
ROIC -124.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: 2.40
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-85.46-39.71-18.88
Net Income-82.74-37.61-33.78
Shares Outstanding34.3126.444.01
Earnings Per Share-2.41-1.42-8.42
Operating Cash Flow-73.68-35.45-10.99
Capital Expenditures-0.27-0.36-0.04
Free Cash Flow-73.95-35.81-11.03
Cash & Equivalents91.7210853.35
Net Cash / Debt91.7210853.35
Book Value81.70104-31.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name resTORbio, Inc.
Country United States
Employees 12
CEO Chen Schor

Stock Information

Ticker Symbol TORC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TORC
IPO Date January 26, 2018


resTORbio, Inc., a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to treat neurodegenerative diseases. resTORbio, Inc. was founded in 2016 and is headquartered in Boston, Massachusetts.